CytomX Therapeutics (CTMX) News Today $0.89 +0.02 (+2.68%) As of 01/24/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Assenagon Asset Management S.A. Sells 1,044,318 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)Assenagon Asset Management S.A. reduced its stake in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 63.5% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 599,850 shares of the biotechnology company'January 25 at 3:15 AM | marketbeat.comShort Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Drops By 13.4%CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 4,800,000 shares, a decline of 13.4% from the December 15th total of 5,540,000 shares. Based on an average daily volume of 1,230,000 shares, the short-interest ratio is currently 3.9 days.January 19, 2025 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJanuary 19, 2025 | americanbankingnews.comBay Area biotech firm CytomX, once worth $2.3 billion, lays off 40% of staffJanuary 15, 2025 | msn.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Recommendation of "Moderate Buy" by AnalystsShares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) have been given an average rating of "Moderate Buy" by the six ratings firms that are presently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and three have given a buy ratinJanuary 14, 2025 | marketbeat.comCytomX Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for CytomX Therapeutics (CTMX)January 8, 2025 | markets.businessinsider.comCytomX Therapeutics Inc.: CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateJanuary 7, 2025 | finanznachrichten.deCytomX Therapeutics (CTMX) Gets a Buy from BarclaysJanuary 7, 2025 | markets.businessinsider.comCytomX Therapeutics (CTMX) Receives a Buy from WedbushJanuary 7, 2025 | markets.businessinsider.comCytomX falls after portfolio shakeup, job cutsJanuary 7, 2025 | msn.comCytomX Therapeutics to Cut 40% of WorkforceJanuary 7, 2025 | marketwatch.comCytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateJanuary 7, 2025 | markets.businessinsider.comPeninsula biotech to lay off 40% of workforce as it restructuresJanuary 7, 2025 | bizjournals.comCytomX Therapeutics (NASDAQ:CTMX) Receives "Neutral" Rating from HC WainwrightHC Wainwright reissued a "neutral" rating on shares of CytomX Therapeutics in a research report on Tuesday.January 7, 2025 | marketbeat.comCytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and Provides Corporate UpdateJanuary 6, 2025 | globenewswire.comShort Interest in CytomX Therapeutics, Inc. (NASDAQ:CTMX) Expands By 26.2%CytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 5,540,000 shares, a growth of 26.2% from the November 30th total of 4,390,000 shares. Based on an average daily volume of 1,160,000 shares, the days-to-cover ratio is presently 4.8 days.December 31, 2024 | marketbeat.comCytomX heading into ‘major catalyst year,’ says JonesResearchDecember 31, 2024 | markets.businessinsider.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from AnalystsCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned an average rating of "Moderate Buy" from the six ratings firms that are presently covering the stock, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold recommendation and three have assignDecember 20, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Shares Cross Below Two Hundred Day Moving Average - Time to Sell?CytomX Therapeutics (NASDAQ:CTMX) Share Price Crosses Below 200-Day Moving Average - What's Next?December 18, 2024 | marketbeat.comJanus Henderson Group PLC Has $5.70 Million Holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX)Janus Henderson Group PLC decreased its stake in shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 23.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,809,518 sharesDecember 10, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 21.7% in NovemberCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) saw a significant decline in short interest in the month of November. As of November 15th, there was short interest totalling 4,440,000 shares, a decline of 21.7% from the October 31st total of 5,670,000 shares. Based on an average daily volume of 809,100 shares, the short-interest ratio is currently 5.5 days.November 30, 2024 | marketbeat.comCytomX Therapeutics to Present at the 36th Annual Piper Sandler Healthcare ConferenceNovember 27, 2024 | globenewswire.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Average Recommendation of "Moderate Buy" from BrokeragesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold rating and three have issued a buyNovember 25, 2024 | marketbeat.comResearch Analysts Set Expectations for CTMX FY2024 EarningsCytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) - Analysts at HC Wainwright raised their FY2024 earnings estimates for shares of CytomX Therapeutics in a report issued on Monday, November 11th. HC Wainwright analyst M. Kapoor now expects that the biotechnology company will post earnings perNovember 13, 2024 | marketbeat.comCytomX Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 10, 2024 | uk.finance.yahoo.comCytomX Therapeutics price target lowered to $3.25 from $3.50 at Piper SandlerNovember 9, 2024 | markets.businessinsider.comCytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below Fifty Day Moving Average - Here's WhyCytomX Therapeutics (NASDAQ:CTMX) Share Price Passes Below 50-Day Moving Average - Here's WhyNovember 9, 2024 | marketbeat.comQ3 2024 CytomX Therapeutics Inc Earnings CallNovember 8, 2024 | uk.finance.yahoo.comCytomX Therapeutics Reports Q3 Progress and GrowthNovember 8, 2024 | markets.businessinsider.comCytomX Therapeutics (CTMX) Receives a Buy from BarclaysNovember 8, 2024 | markets.businessinsider.comCytomX Therapeutics, Inc. (CTMX) Q3 2024 Earnings Call TranscriptNovember 8, 2024 | seekingalpha.comCytomX Therapeutics Inc (CTMX) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ...November 8, 2024 | finance.yahoo.comCytomX Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 7, 2024 | globenewswire.comEarnings To Watch: CytomX Therapeutics Inc (CTMX) Reports Q3 2024 ResultNovember 6, 2024 | finance.yahoo.comCytomX Therapeutics (CTMX) Scheduled to Post Quarterly Earnings on ThursdayCytomX Therapeutics (NASDAQ:CTMX) will be releasing earnings after the market closes on Thursday, November 7, Zacks reports.November 1, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the six analysts that are currently covering the company, MarketBeat reports. Three analysts have rated the stock with a hold recommendation and three have given a buy recommendatiOctober 31, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Short Interest Down 10.5% in SeptemberCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) was the recipient of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 6,250,000 shares, a decrease of 10.5% from the September 15th total of 6,980,000 shares. Based on an average trading volume of 686,500 shares, the short-interest ratio is currently 9.1 days.October 17, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comH.C. Wainwright Sticks to Their Hold Rating for CytomX Therapeutics (CTMX)September 14, 2024 | markets.businessinsider.comCytomX Therapeutics' (CTMX) "Neutral" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a research report on Friday.September 13, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Average Rating of "Moderate Buy" by AnalystsCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on the company. ThSeptember 11, 2024 | marketbeat.comCytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY®, in a Phase 1 Study in Patients with Solid TumorsSeptember 9, 2024 | globenewswire.comInsider Selling: CytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sells 13,898 Shares of StockAugust 23, 2024 | insidertrades.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) CEO Sean A. Mccarthy Sells 13,898 SharesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) CEO Sean A. Mccarthy sold 13,898 shares of the stock in a transaction that occurred on Tuesday, August 20th. The stock was sold at an average price of $1.23, for a total transaction of $17,094.54. Following the completion of the transaction, the chief executive officer now owns 657,851 shares in the company, valued at approximately $809,156.73. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.August 22, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Stock Rating Reaffirmed by HC WainwrightHC Wainwright reaffirmed a "neutral" rating on shares of CytomX Therapeutics in a report on Thursday.August 22, 2024 | marketbeat.comAssenagon Asset Management S.A. Acquires 833,825 Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX)Assenagon Asset Management S.A. boosted its holdings in CytomX Therapeutics, Inc. (NASDAQ:CTMX - Free Report) by 206.0% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,238,499 shares of the biotechnology company's stAugust 22, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Given Consensus Rating of "Moderate Buy" by BrokeragesCytomX Therapeutics, Inc. (NASDAQ:CTMX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the six analysts that are presently covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a hold rating and three have issued a buy rating on theAugust 17, 2024 | marketbeat.comCytomX Therapeutics (NASDAQ:CTMX) Posts Earnings Results, Misses Estimates By $0.01 EPSCytomX Therapeutics (NASDAQ:CTMX - Get Free Report) issued its quarterly earnings data on Thursday. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). CytomX Therapeutics had a net margin of 13.87% and a negative return on equity of 30.70%. The firm had revenue of $25.12 million during the quarter, compared to the consensus estimate of $21.79 million. During the same quarter in the prior year, the business earned ($0.02) earnings per share.August 11, 2024 | marketbeat.comCytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | insidermonkey.com Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address CTMX Media Mentions By Week CTMX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CTMX News Sentiment▼1.250.59▲Average Medical News Sentiment CTMX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CTMX Articles This Week▼12▲CTMX Articles Average Week Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Heron Therapeutics News Today Amylyx Pharmaceuticals News Today Neurogene News Today Atai Life Sciences News Today DiaMedica Therapeutics News Today UroGen Pharma News Today Eledon Pharmaceuticals News Today Lifecore Biomedical News Today Foghorn Therapeutics News Today Benitec Biopharma News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CTMX) was last updated on 1/27/2025 by MarketBeat.com Staff From Our Partners Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredMan Who Called Nvidia Says: “Your Retirement Is Inside This Building.”In 2016, Jeff Brown called Nvidia at a split-adjusted 66 cents. The company just became the world's third $...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
